AstraZeneca plc (LON:AZN) has been assigned a GBX 4,900 ($63.28) price target by research analysts at Jefferies Group LLC in a research report issued on Monday. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Jefferies Group LLC’s price target suggests a potential upside of 3.82% from the company’s previous close.

Other analysts have also issued research reports about the company. Liberum Capital reissued a “buy” rating and set a GBX 5,500 ($71.03) price objective on shares of AstraZeneca plc in a research note on Tuesday, May 23rd. UBS AG set a GBX 5,150 ($66.51) price objective on AstraZeneca plc and gave the company a “neutral” rating in a research note on Tuesday, June 27th. J P Morgan Chase & Co reissued a “neutral” rating on shares of AstraZeneca plc in a research note on Thursday, July 13th. Credit Suisse Group dropped their price objective on AstraZeneca plc from GBX 5,000 ($64.57) to GBX 4,700 ($60.70) and set a “neutral” rating for the company in a research note on Friday, July 28th. Finally, Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($50.37) price objective on AstraZeneca plc and gave the company a “sell” rating in a research note on Wednesday, August 2nd. Three analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of GBX 5,027.45 ($64.93).

AstraZeneca plc (LON:AZN) opened at 4703.50 on Monday. The company’s market cap is GBX 59.55 billion. The firm’s 50-day moving average is GBX 4,556.15 and its 200 day moving average is GBX 4,880.61. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00.

WARNING: “Jefferies Group LLC Reiterates GBX 4,900 Price Target for AstraZeneca plc (AZN)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/18/jefferies-group-llc-reiterates-gbx-4900-price-target-for-astrazeneca-plc-azn.html.

In related news, insider Nazneen Rahman purchased 39 shares of AstraZeneca plc stock in a transaction dated Thursday, July 27th. The stock was purchased at an average cost of GBX 4,370 ($56.44) per share, for a total transaction of £1,704.30 ($2,201.08).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.